Inactive Instrument

Coland Holdings Limited Stock

Equities

4144

KYG2379A1094

Pharmaceuticals

Dynamic Chart
Coland Holdings Limited Announces the Financial Supervisory Commission Approval of the Termination of the Its Public Company Status Since October 30, 2020 CI
Coland Holdings Limited Reports Impairment of Assets for the Second Quarter of 2020 CI
Coland Holdings Limited Reports Earnings Results for the Second Quarter Ended June 30, 2020 CI
Oceanic World Sub Corp entered into Letter of Intent to acquire Coland Holdings Limited for TWD 2 billion. CI
Golden Hexagon Investments Limited made a tender offer to acquire an additional 15% stake in Coland Holdings Limited for approximately TWD 310 million. CI
Coland Holdings Limited Reports Earnings Results for the First Quarter Ended March 31, 2020 CI
Coland Holdings Limited Announces the Appointment of Tsao Johua as Company's New Head of Company Secretary CI
Coland Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2019 CI
Coland Holdings Limited Reports Earnings Results for the Third Quarter Ended September 30, 2019 CI
Coland Holdings Limited Reports Earnings Results for the Second Quarter Ended June 30, 2019 CI
Coland Holdings Limited Reports Earnings Results for the First Quarter Ended March 31, 2019 CI
Coland Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2018 CI
Coland Holdings Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018; Reports Impairment Charges for the Third Quarter of 2018 CI
Coland Holdings Limited announced that it expects to receive TWD 405 million in funding CI
Coland Holdings Seeks Acquisitions CI
More news
Managers TitleAgeSince
Chief Executive Officer 53 16-06-30
Director/Board Member - 08-06-30
Investor Relations Contact - -
Members of the board TitleAgeSince
Director/Board Member - 10-12-04
Chairman 75 10-12-04
Director/Board Member - 10-12-04
More insiders
Coland Holdings Limited is a Taiwan-based company principally engaged in the development and distribution of pharmaceuticals. The Company provides products for the treatment of hepatitis, respiratory system diseases, urinary systems, cardiovascular and nervous system diseases. The Company also offers medical equipment, spinal instrumentations and antibiotics. Its products include Adefovir Dipivoxil Tablets, Mycophenolate Mofetil Dispersible Tablets, Tiotropium Bromide Powder For Inhalation, Amoxicillin Sodium and Clavulanate Potassium for Injection and Lamivudine Tablets. The Company operates its businesses primarily in Mainland China.
More about the company